Cosmo Pharmaceuticals

Cosmo is an emerging fully-integrated specialty pharmaceutical company that aims to become a global leader in the market for optimized therapies for selected gastro-intestinal diseases. The company’s proprietary clinical development pipeline specifically addresses innovative treatments for Inflammatory Bowel Diseases (IBD), such as Ulcerative Colitis and Crohn’s Disease, as well as for colon infections. Cosmo went public on the SWX Swiss Exchange in 2007.

INVISION sold its stake in Cosmo Pharmaceuticals in the public stock market in 2008.

Website: www.cosmopharma.com